Add like
Add dislike
Add to saved papers

Prospective multicenter study of the low-profile Relay stent-graft in patients with thoracic aortic disease: the RE-GENERATION study.

PURPOSE: To evaluate the early safety and clinical performance of the new low-profile RelayPro Thoracic Stent-Graft System in patients with thoracic aortic disease.

METHODS: This was an international, prospective, single-arm study in patients diagnosed with thoracic aorta disease (aneurysm, pseudoaneurysm, dissection, penetrating aortic ulcer [PAU], or intramural hematoma) and treated with a RelayPro stent-graft (in bare stent and/or non-bare stent configurations). The primary endpoints were freedom from aneurysm or dissection-related mortality and stent-graft performance.

RESULTS: A total of 31 patients were treated with the RelayPro thoracic stent-graft between 2014 and 2015 at eight sites in Italy and Spain. Mean age was 72.1 (±10.2) years and 77% were male, 74% with hypertension, 42% with a history of smoking. Twenty-four (77%) had aneurysms (fusiform in 46%, saccular in 42%, pseudoaneurysm in 12%); five (16%) had PAU; and two (6%) had chronic Type B dissection. Mean vascular access diameter was 9.1 mm (6-13 mm); seven patients (23%) had vascular access of 7 mm or less. Technical success was 100% (primary, 90%; assisted primary, 10%). Freedom from aneurysm/dissection-related mortality through 30 days was 100%. Freedom from device-related major adverse events through 30 days was 94%. At one year, there was one (3%) type Ib and one (3%) type II endoleak, one (3%) non-aneurysm-related late death, and one (3%) secondary intervention (to correct type Ib endoleak).

CONCLUSION: The RelayPro has a 3-4 French profile reduction to allow endovascular repair of thoracic aortic disease in patients with smaller anatomies. This study shows good initial stent-graft performance and a favorable early safety profile.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app